Bioventus (BVS) Other Non-Current Liabilities (2021 - 2026)

Bioventus (BVS) has 6 years of Other Non-Current Liabilities data on file, last reported at $14.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 35.02% year-over-year to $14.3 million; the trailing twelve-month figure through Mar 2026 stood at $14.3 million (down 35.02% YoY), and the FY2025 full-year result was $15.3 million, down 33.56% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $14.3 million, down from $15.3 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $32.0 million in Q3 2023 and bottomed at $14.3 million in Q1 2026.
• The 5-year median for Other Non-Current Liabilities is $21.3 million (2025), against an average of $22.0 million.
• The widest annual swing landed in 2023, when Other Non-Current Liabilities soared 89.62%; it then sank 35.61% in 2024.
• A 5-year view of Other Non-Current Liabilities shows it stood at $17.4 million in 2022, then surged by 60.25% to $27.9 million in 2023, then retreated by 17.3% to $23.1 million in 2024, then slumped by 33.56% to $15.3 million in 2025, then decreased by 6.93% to $14.3 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $14.3 million (Q1 2026), $15.3 million (Q4 2025), and $20.5 million (Q3 2025), per Business Quant data.

Peer Comparison